Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients - a multicenter retrospective observational study

被引：3

作者：

Shimony, Shai ^{[1
,2
]}

Yeshurun, Moshe ^{[1
,2
]}

Wolach, Ofir ^{[1
,2
]}

Ram, Ron ^{[2
,3
]}

Rozovski, Uri ^{[1
,2
]}

Shargian, Liat ^{[1
,2
]}

Zukerman, Tsila ^{[4
,5
]}

Amit, Odelia ^{[2
,3
]}

Bar-On, Yael ^{[2
,3
]}

Krayem, Baher ^{[4
,5
]}

Avni, Batya ^{[6
,7
]}

Peretz, Galit ^{[8
,9
]}

Raanani, Pia ^{[1
,2
]}

Pasvolsky, Oren ^{[1
,2
]}

机构：

[1] Rabin Med Ctr, Davidoff Canc Ctr, Inst Hematol, Jabotinski 39, Petah Tiqwa, Israel

[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[3] Tel Aviv Sourasky Med Ctr, Inst Hematol, Tel Aviv, Israel

[4] Rambam Hlth Care Campus, Dept Hematol & Bone Marrow Transplantat, Haifa, Israel

[5] Rappaport Fac Med Technion, Haifa, Israel

[6] Hadassah Med Ctr, Inst Hematol, Jerusalem, Israel

[7] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel

[8] Soroka Med Ctr, Dept Hematol & Bone Marrow Transplantat, Beer Sheva, Israel

[9] Fac Med, Beer Sheva, Israel

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 10期

关键词：

Acute myeloid leukemia; FLT3; inhibitors; post-transplantation maintenance; ACUTE MYELOID-LEUKEMIA; CHEMOTHERAPY; ADULTS;

D O I：

10.1080/10428194.2021.1913145

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The role of post allogeneic stem-cell transplantation (AlloSCT) FLT3 inhibition for acute myeloid leukemia in the real-world setting is unclear, especially in the era of widespread pre-transplant use of tyrosine kinase inhibitors (TKIs). In a multicenter nationwide study, we assessed 41 patients who were treated with post-transplant TKIs (sorafenib, n = 23, midostaurin, n = 18). The majority also received TKIs pre-transplant (n = 32, 79%). After a median follow up of 10 months post-transplant (range 3-53.6), 29 patients (71%) were alive and in complete remission. Similar results were seen in a subgroup analysis of pre-transplant TKI recipients (78%). In Univariate analysis, HCT-CI score < 4 and Type of TKI (sorafenib versus midostaurin) predicted longer overall survival. Seventeen patients (41%) suffered from side effects and seven patients (17%) stopped TKI therapy due to adverse events. Overall, our data suggest that post-transplant use of TKIs is safe and effective in an era of their widespread use prior to AlloSCT.

引用

页码：2475 / 2481

页数：7

共 20 条

[1] Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation [J].

Antar, Ahmad ;

Kharfan-Dabaja, Mohamed A. ;

Mahfouz, Rami ;

Bazarbachi, Ali .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (05) :298-302

[2] Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update [J].

Battipaglia, Giorgia ;

Massoud, Radwan ;

Ahmed, Syed Osman ;

Legrand, Ollivier ;

El Cheikh, Jean ;

Youniss, Riad ;

Aljurf, Mahmoud ;

Mohty, Mohamad ;

Bazarbachi, Ali .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (08) :506-508

[3] Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia [J].

Battipaglia, Giorgia ;

Ruggeri, Annalisa ;

Massoud, Radwan ;

El Cheikh, Jean ;

Jestin, Matthieu ;

Antar, Ahmad ;

Ahmed, Syed Osman ;

Rasheed, Walid ;

Shaheen, Marwan ;

Belhocine, Ramdane ;

Brissot, Eolia ;

Dulery, Remy ;

Eder, Sandra ;

Giannotti, Federica ;

Isnard, Francoise ;

Lapusan, Simona ;

Rubio, Marie-Therese ;

Vekhoff, Anne ;

Aljurf, Mahmoud ;

Legrand, Ollivier ;

Mohty, Mohamad ;

Bazarbachi, Ali .

CANCER, 2017, 123 (15) :2867-2874

[4] Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control study [J].

Berger, Tamar ;

Rozovski, Uri ;

Moshe, Yakir ;

Yaari, Shilo ;

Frisch, Avraham ;

Hellmann, Ilana ;

Apel, Arie ;

Aviram, Adina ;

Koren-Michowitz, Maya ;

Yeshurun, Moshe ;

Ram, Ron ;

Raanani, Pia ;

Ofran, Yishai ;

Wolach, Ofir .

ANNALS OF HEMATOLOGY, 2019, 98 (12) :2711-2717

[5] Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis [J].

Brunet, Salut ;

Labopin, Myriam ;

Esteve, Jordi ;

Cornelissen, Jan ;

Socie, Gerard ;

Iori, Anna P. ;

Verdonck, Leo F. ;

Volin, Liisa ;

Gratwohl, Alois ;

Sierra, Jorge ;

Mohty, Mohamad ;

Rocha, Vanderson .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (07) :735-741

[6] Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission [J].

Brunner, Andrew M. ;

Li, Shuli ;

Fathi, Amir T. ;

Wadleigh, Martha ;

Ho, Vincent T. ;

Collier, Kerry ;

Connolly, Christine ;

Ballen, Karen K. ;

Cutler, Corey S. ;

Dey, Bimalangshu R. ;

El-Jawahri, Areej ;

Nikiforow, Sarah ;

McAfee, Steven L. ;

Koreth, John ;

Deangelo, Daniel J. ;

Alyea, Edwin P. ;

Antin, Joseph H. ;

Spitzer, Thomas R. ;

Stone, Richard M. ;

Soiffer, Robert J. ;

Chen, Yi-Bin .

BRITISH JOURNAL OF HAEMATOLOGY, 2016, 175 (03) :496-504

[7] Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN) [J].

Burchert, Andreas ;

Bug, Gesine ;

Fritz, Lea V. ;

Finke, Juergen ;

Stelljes, Matthias ;

Roellig, Christoph ;

Wollmer, Ellen ;

Waesch, Ralph ;

Bornhaeuser, Martin ;

Berg, Tobias ;

Lang, Fabian ;

Ehninger, Gerhard ;

Serve, Hubert ;

Zeiser, Robert ;

Wagner, Eva-Maria ;

Kroeger, Nicolaus ;

Wolschke, Christine ;

Schleuning, Michael ;

Goetze, Katharina S. ;

Schmid, Christoph ;

Crysandt, Martina ;

Esseling, Eva ;

Wolf, Dominik ;

Wang, Ying ;

Boehm, Alexandra ;

Thiede, Christian ;

Haferlach, Torsten ;

Michel, Christian ;

Bethge, Wolfgang ;

Wuendisch, Thomas ;

Brandts, Christian ;

Harnisch, Susanne ;

Wittenberg, Michael ;

Hoeffkes, Heinz-Gert ;

Rospleszcz, Susanne ;

Burchardt, Alexander ;

Neubauer, Andreas ;

Brugger, Markus ;

Strauch, Konstantin ;

Schade-Brittinger, Carmen ;

Metzelder, Stephan K. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (26) :2993-3002

[8] Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel [J].

Doehner, Hartmut ;

Estey, Elihu ;

Grimwade, David ;

Amadori, Sergio ;

Appelbaum, Frederick R. ;

Buechner, Thomas ;

Dombret, Herve ;

Ebert, Benjamin L. ;

Fenaux, Pierre ;

Larson, Richard A. ;

Levine, Ross L. ;

Lo-Coco, Francesco ;

Naoe, Tomoki ;

Niederwieser, Dietger ;

Ossenkoppele, Gert J. ;

Sanz, Miguel ;

Sierra, Jorge ;

Tallman, Martin S. ;

Tien, Hwei-Fang ;

Wei, Andrew H. ;

Lowenberg, Bob ;

Bloomfield, Clara D. .

BLOOD, 2017, 129 (04) :424-447

[9] Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007 [J].

Dores, Graca M. ;

Devesa, Susan S. ;

Curtis, Rochelle E. ;

Linet, Martha S. ;

Morton, Lindsay M. .

BLOOD, 2012, 119 (01) :34-43

[10] Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm [J].

Fröhling, S ;

Schlenk, RF ;

Breitruck, J ;

Benner, A ;

Kreitmeier, S ;

Tobis, K ;

Döhner, H ;

Döhner, K .

BLOOD, 2002, 100 (13) :4372-4380

← 1 2 →